The clinical trial, which also involved Vall d’Hebron, shows that the new therapy improves survival by 86% in patients with thymidine kinase 2 deficiency (TK2d).

The project aims to improve prevention, diagnosis, and treatment through computational biomedicine, innovative therapies, and the transfer of knowledge into clinical practice.

The European project DISCOvERIE, led by Vall d’Hebron, paves the way for more personalized diagnoses and new treatment strategies to improve patients’ quality of life.

The Stroke Research and the Neurovascular Diseases groups lead innovative research projects in both clinical and translational areas.

The study analyzes the cost-effectiveness and environmental impact of reusable trocars compared to single-use trocars in laparoscopic surgery.

The two sports legends took part in the final panel of the 2ond International Congress on Health Communication at Vall d’Hebron, speaking about their role as ambassadors for health institutions.

The first day of Vall d’Hebron’s Health Communication Congress debates how to communicate in the midst of war, how to manage social media presence, and how to integrate art into healthcare.

The meeting takes place within the framework of Healing Arts Barcelona, with the aim of exploring and debating how participation in artistic activities can help improve physical and mental health.

UNCAN-Connect aims to enhance interoperability and accelerate scientific progress by supporting open science and strengthening collaborations.

The meeting focused on the new VHIR Strategic Plan being developed for the period 2026-2030.

Between 6 and 16 October, the Wellbeing Days took place with activities designed to strengthen the culture of wellbeing within the organisation.

A strategic agreement to enhance cooperation between science, technology, and health.

Experts from around the world will debate on October 23 and 24 about communication in war zones, the role of public figures as health ambassadors, new professional profiles, and whether or not to be present on social media, among other topics.

It’s one of Europe’s leading biotechnology events and one of the largest in the world.

The donation ensures the continuity of the project and guarantees support for people with PID throughout adulthood.

The work represents a paradigm shift in the clinical approach to this chronic, multifactorial disease, based on the clinical context of each patient and not only on weight loss.

The project on the implementation of a protocol for assessing acute urinary retention using ultrasound in stroke patients has been awarded in the Research Grants category.

The event has promoted collaboration within the VHIR innovation ecosystem and has highlighted the innovation model to facilitate capital investment for our spin-offs.

The team will develop a new medical tool to facilitate the removal of blood clots in blood vessels after a stroke in a safer and more effective manner.

Her nomination means that she will represent UPF in the national competition held annually.

Areas of interest include the development of new drugs, medical devices and digital health solutions, as well as new therapies and diagnostic technologies.

The HUVH Biobank has been recognized for its sustainability and efficiency in laboratory cold storage.

The Lancet Neurology publishes the new criteria, the result of a global expert consensus led by Dr Xavier Montalban.

The results of a phase 3 clinical trial show that orforglipron reduces body weight by an average of 11% and improves cardiovascular risk factors.